<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269696</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5101090</org_study_id>
    <nct_id>NCT02269696</nct_id>
  </id_info>
  <brief_title>The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients</brief_title>
  <official_title>The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the effects of metoprolol on anaesthesia and the need for
      perioperative analgesics in patients undergoing breast surgery. With 12 months follow-up the
      incidence of pain and life satisfaction will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to test the effects of intraoperative metoprolol on 1)
      anaesthetic and alagesic use 2) pain during the early postoperative period and 3) the
      incidence of pain and lide satisfaction up to 12 months after the surgery. Adverse effects
      will be recorded as safety measures.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn
  </why_stopped>
  <start_date type="Anticipated">March 21, 2018</start_date>
  <completion_date type="Anticipated">March 21, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anaesthesia</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Total consumption of desflurane</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anaesthesia</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Total consumption of remifentanil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>First 4 postoperative hours</time_frame>
    <description>Total analgesics consumption</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>First 4 postoperative hours</time_frame>
    <description>Time to analgesics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>First 4 postoperative hours</time_frame>
    <description>Numerical pain scale (0 = no pain, 10 = most pain) at rest and at movement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term pain</measure>
    <time_frame>3 months</time_frame>
    <description>The incidence and the level of pain at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term pain</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence and the level of pain at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Perioperative</time_frame>
    <description>Number of patients with adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution to the central nervous system</measure>
    <time_frame>Perioperative</time_frame>
    <description>Cerebro spinal fluid and blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life satisfaction</measure>
    <time_frame>1 year</time_frame>
    <description>Life satisfaction in a Likerts scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>1 year</time_frame>
    <description>Spielberg State-Trait Anxiety Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>1 year</time_frame>
    <description>Beck Depression Inventory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metoprolol infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal volume of saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Intraoperative metoprolol infusion.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Seloken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Equal of volume compared to metoprolol.</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>NaCl 0,9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective breast surgery due to breast cancer

          -  Voluntary

          -  BMI ≥ 18 and ≤ 35 kg/m2

          -  ASA 1-3

          -  No regular use of beta-blockers or during the last 72 hours

          -  No contraindications to beta-blockers

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  AV-block, degree II or III

          -  Untreated cardiac insufficiency

          -  Sinus bradycardia, heart rate &lt; 45 / min or symptoms

          -  Sick sinus syndrome

          -  Cardiogenic shock

          -  Severe peripheral vascular disorder

          -  Systolic blood pressure &lt; 100 mmHg

          -  Long PQ-time, &gt; 0,24 seconds

          -  Known hypersensitivity to beta-blockers or the ingredients of the drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kuopio University Hospital</investigator_affiliation>
    <investigator_full_name>Lasse Harkanen</investigator_full_name>
    <investigator_title>DR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Mastodynia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

